MK-677 · Research brief

What Is MK677 Same as MK-677? (Nomenclature Explained)

Real Peptides Research TeamEditorial

Updated April 10, 202610 min read

59 WORDS

Short answer

Research peptide nomenclature causes more confusion than it should. MK677 and MK-677 appear in different publications, product listings, and research protocols as if they're distinct compounds. But they reference the same molecule: ibutamoren, a non-peptide growth hormone secretagogue that mimics ghrelin's action on the GHSR-1a receptor. The hyphen versus no-hyphen variation is a formatting convention, not a chemical distinction.

Key takeaways

MK677 and MK-677 are the same compound. Ibutamoren, a non-peptide growth hormone secretagogue with a 24-hour half-life and oral bioavailability exceeding 60%.
The hyphen variation is a formatting convention from the original Merck designation, not a chemical distinction. Both forms reference CID 9939050 in PubChem.
Ibutamoren activates the GHSR-1a receptor to stimulate pulsatile GH release, increasing serum IGF-1 by 60–90% at 25mg daily dosing without suppressing endogenous GH production.
Research applications include sarcopenia intervention, bone density studies, cachexia treatment, and sleep architecture modulation. With Phase II trial data showing lean mass gains and improved functional outcomes in elderly populations.
Supplier verification is critical. Third-party CoA documents confirming HPLC purity and mass spectrometry are essential to ensure MK677 formulations match declared identity and concentration.

Our team has worked with research-grade peptides and secretagogues across hundreds of lab applications. The naming inconsistency trips up even experienced researchers when cross-referencing studies or sourcing compounds from different suppliers.

Is MK677 the same compound as MK-677?

Yes. MK677 and MK-677 are identical. Both designations refer to ibutamoren, a selective agonist of the ghrelin receptor (growth hormone secretagogue receptor 1a). The hyphenated form (MK-677) appears more frequently in peer-reviewed literature, while MK677 without the hyphen is common in supplier catalogues and informal research discussions. Chemically, structurally, and pharmacologically, they are the same molecule with the same mechanism of action, half-life (approximately 24 hours), and receptor affinity profile.

The source of confusion isn't limited to the hyphen. Ibutamoren has been referenced in published research under at least four different designations: MK-677 (Merck designation from early development), MK677 (informal shorthand), L-163,191 (early experimental code), and ibutamoren mesylate (the salt form used in most formulations). None of these represent different compounds. They're nomenclature variations for the same growth hormone secretagogue that emerged at different stages of research and commercial development. This article covers exactly why the naming inconsistency exists, how MK677 differs mechanistically from peptide-based GH secretagogues, what the current research applications are, and how to verify compound identity when sourcing from research suppliers.

MK677 vs MK-677: Chemical Identity and Nomenclature Origins

MK677 same as MK-677 because both derive from the original Merck compound designation assigned during Phase I clinical trials in the 1990s. Merck & Co. developed ibutamoren as part of a broader secretagogue research program exploring non-peptide alternatives to GHRP-6 and GHRP-2. Earlier peptide-based growth hormone releasers that required frequent injection and had limited oral bioavailability. The "MK" prefix indicated Merck as the originating institution, and 677 was the internal compound tracking number. Publications from that era used MK-677 with a hyphen as the standard research identifier.

As the compound moved into open research and third-party synthesis, the hyphen was often dropped in informal contexts. Supplier catalogues, forum discussions, and non-peer-reviewed summaries frequently write it as MK677. Some databases index both forms separately, creating the false impression of two distinct molecules when cross-referencing studies. PubChem lists ibutamoren under CID 9939050 with MK-677 as the primary synonym and MK677 as a secondary variant. Confirming they reference the same chemical entity (2-amino-2-methyl-N-[1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide).

The structural uniqueness of MK677 lies in its non-peptide backbone. Unlike GHRP analogues built from amino acid chains, ibutamoren is a spiro-indane derivative. A small-molecule mimic of ghrelin that binds the GHSR-1a receptor without undergoing proteolytic degradation in the gut. This allows oral administration with bioavailability exceeding 60%, a pharmacokinetic advantage peptide secretagogues cannot match. The half-life of approximately 24 hours means once-daily dosing maintains therapeutic plasma levels, contrasting sharply with hexarelin or GHRP-2, which require multiple daily injections to avoid trough periods.

Mechanism of Action: How MK-677 Functions as a Growth Hormone Secretagogue

MK-677 operates by binding selectively to the growth hormone secretagogue receptor type 1a (GHSR-1a), the same receptor activated by endogenous ghrelin. This binding triggers a cascade that stimulates pulsatile growth hormone release from somatotroph cells in the anterior pituitary. Mimicking the body's natural GH secretion pattern rather than introducing exogenous GH directly. The resulting elevation in serum GH levels secondarily increases hepatic production of IGF-1 (insulin-like growth factor 1), the primary mediator of GH's anabolic and metabolic effects.

Clinical pharmacology studies published in the Journal of Clinical Endocrinology & Metabolism demonstrate that MK677 same as MK-677 produces dose-dependent increases in both GH and IGF-1. At 25mg daily oral dosing, mean serum IGF-1 levels increased by 60–90% from baseline within two weeks, with peak elevations occurring 4–6 hours post-administration. Unlike exogenous GH injection, which suppresses endogenous production through negative feedback, MK-677 preserves the hypothalamic-pituitary axis because it works through the ghrelin pathway. The body continues producing GHRH and responds to normal regulatory signals.

The compound's selectivity for GHSR-1a over other ghrelin receptor subtypes minimises off-target effects. It does not bind glucocorticoid, mineralocorticoid, or androgen receptors. Meaning it lacks the cortisol elevation or hormonal disruption seen with some older secretagogues. The primary metabolic consequence is increased appetite, which stems directly from ghrelin pathway activation. Research participants in Phase II trials reported 15–30% increases in caloric intake during the first four weeks of administration, driven by enhanced orexigenic signalling in the arcuate nucleus.

GH pulse amplitude on MK-677 mirrors physiological secretion patterns observed during deep sleep. The compound does not induce supraphysiological spikes that risk receptor downregulation or metabolic dysregulation. This makes it mechanistically distinct from bolus GH injection protocols, where trough periods alternate with extreme peaks. Continuous daily administration sustains elevated baseline GH without ablating pulsatility entirely.

Research Applications and Current Study Contexts for MK-677

MK677 appears in peer-reviewed literature across three primary research domains: sarcopenia and age-related muscle loss, bone density preservation in osteopenic populations, and metabolic profiling in GH-deficient states. A 2008 randomised controlled trial published in the Annals of Internal Medicine enrolled 65 adults aged 60–81 and administered 25mg MK-677 daily for 12 months. Results showed significant increases in lean body mass (mean +1.1 kg) and bone mineral density at the femoral neck (+0.8% vs baseline), with no change in visceral adiposity. Suggesting selective anabolic effects on muscle and bone without fat accumulation.

Another application area is metabolic research in cachexia and wasting conditions. Because MK-677 increases appetite alongside GH secretion, it has been studied as a potential intervention in populations where caloric intake and anabolism are both impaired. Hip fracture recovery, chronic obstructive pulmonary disease (COPD), and post-surgical convalescence. A 2001 study in elderly hip fracture patients found that MK-677 administration (25mg daily for eight weeks) increased gait speed and functional independence measures compared to placebo, likely through combined effects of enhanced muscle protein synthesis and improved nutritional intake.

Sleep architecture research represents a third active domain. MK-677 administration has been shown to increase REM sleep duration by 20–50% and enhance slow-wave sleep depth, measured via polysomnography. This effect appears mediated through ghrelin's central nervous system actions rather than GH elevation per se. Ghrelin receptors in the hypothalamus modulate sleep-wake cycles independently of somatotroph stimulation. For researchers investigating sleep disorders or circadian disruption, MK-677 offers a pharmacological tool to manipulate sleep stages without sedative-hypnotic mechanisms.

Our peptide line includes MK 677 synthesised under precise amino-acid sequencing protocols and verified for purity. Designed for researchers who need batch-to-batch consistency in growth hormone secretagogue studies. Lab reliability depends on knowing exactly what you're working with.

MK677 Same as MK-677: Comparison of Research Formulations

Formulation Type	Typical Purity Range	Oral Bioavailability	Shelf Stability (Lyophilised)	Common Research Dose Range	Professional Assessment
Ibutamoren Mesylate (Salt Form)	98–99.5% HPLC	60–65%	24 months at −20°C	10–25mg daily	Industry-standard form. Highest solubility and batch consistency for controlled studies
Free-Base Ibutamoren	95–98% HPLC	55–60%	18 months at −20°C	10–25mg daily	Less common. Lower aqueous solubility complicates dosing precision in aqueous protocols
Pre-Mixed Suspension (PEG/DMSO)	Variable (85–95%)	Not applicable (already dissolved)	6 months refrigerated	Variable	Convenient but stability concerns. Degrades faster than lyophilised powder
Research-Grade Powder (Third-Party)	90–98% HPLC	60–65%	12–18 months at −20°C	10–25mg daily	Quality depends heavily on supplier. Certificate of analysis (CoA) verification essential

MK677 and MK-677 appear in all four formulation types above with identical chemical structure. The designation does not change the molecule. The mesylate salt form dominates research applications because it dissolves readily in bacteriostatic water and maintains consistent potency across freeze-thaw cycles, critical for multi-dose reconstitution protocols. Free-base formulations require DMSO or ethanol as a carrier solvent, which introduces variables that complicate standardised dosing.

Supplier variability represents the single largest quality risk when sourcing ibutamoren. Some catalogues list MK677 at 99% purity without providing third-party verification. Claims that should trigger immediate CoA requests. Legitimate research-grade suppliers provide batch-specific HPLC and mass spectrometry reports confirming molecular weight, purity percentage, and absence of contaminating peptides or synthesis byproducts. Without these documents, there is no way to verify that MK677 same as MK-677 in both name and actual compound identity.

What If: MK-677 Research Scenarios

What If a Supplier Lists MK677 and MK-677 as Separate Products?

Request certificates of analysis for both listings and compare molecular weight, HPLC retention time, and mass spectrometry data. If the molecular weight matches 624.77 g/mol for the mesylate salt form (or 528.66 g/mol for free base), they are the same compound regardless of naming. Suppliers sometimes create separate listings for marketing segmentation. One targeting peptide researchers, another targeting metabolic study contexts. But the underlying molecule is identical. Any discrepancy in declared purity, concentration, or formulation between the two listings indicates either mislabeling or quality control issues warranting clarification before purchase.

What If Dosing Protocols Reference MK-677 but the Product Arrives Labeled MK677?

Verify batch number and cross-reference the CoA molecular weight with published ibutamoren data. As long as the certificate confirms C27H36N4O5S structure and purity ≥98%, the absence of a hyphen does not affect dosing calculations or research validity. Standardise your internal documentation to one designation (preferably MK-677 to align with peer-reviewed literature) and note the equivalence in your methods section to avoid confusion during manuscript preparation or data review.

What If You Need to Compare Study Results Across Publications Using Different Nomenclature?

Search databases using both "MK-677" and "MK677" as separate queries, then cross-reference CAS number 159752-10-0 or PubChem CID 9939050 to confirm compound identity. Some indexing systems treat hyphenated and non-hyphenated forms as distinct entries, causing relevant studies to be missed in single-query searches. Include ibutamoren and L-163,191 as additional search terms to capture early-phase trials published before the MK-677 designation became standard. This ensures comprehensive literature coverage when building systematic reviews or meta-analyses.

The Definitive Truth About MK-677 Naming Confusion

Here's the honest answer: the MK677 versus MK-677 distinction is entirely superficial. A formatting artefact that persists because different research communities adopted different conventions and neither nomenclature committee enforced a universal standard. The compound's chemical identity, receptor binding profile, pharmacokinetics, and biological mechanism are identical regardless of how the name is written. No credible research has ever reported differing effects based on hyphen presence, because the hyphen does not exist at the molecular level.

The confusion stems from a broader problem in peptide and research compound nomenclature. The absence of enforced naming standards for non-FDA-approved experimental molecules. Pharmaceutical drugs undergo rigorous INN (International Nonproprietary Name) assignment that creates one globally recognised identifier, but research compounds in pre-clinical phases often circulate under multiple designations depending on the originating institution, supplier branding, or informal shorthand adopted by specific research groups. MK-677 had the advantage of early Merck sponsorship, which gave it a relatively stable primary identifier, but even that has fragmented into variants as the compound moved into open synthesis.

What matters in practice is molecular verification, not label formatting. When sourcing ibutamoren for controlled studies, prioritise suppliers who provide third-party mass spectrometry showing molecular ion peaks at m/z 625 (mesylate salt) and HPLC chromatograms with single-peak purity profiles. The label can say MK677, MK-677, or "compound formerly known as L-163,191". None of that changes the requirement for chemical confirmation before dosing protocols begin.

MK-677's mechanism. Selective GHSR-1a agonism producing pulsatile GH secretion. Has been replicated across dozens of independent studies using material from different suppliers, all confirming the same dose-response curves and IGF-1 elevation profiles. That reproducibility exists because the molecule itself is stable and well-characterised, not because researchers unified around a single spelling convention.

Our approach prioritises molecular clarity. Every batch of MK 677 we supply includes third-party verification, exact sequencing documentation, and pharmacological profiling that eliminates guesswork. Research reliability starts with knowing precisely what compound you're working with. Nomenclature is secondary to molecular certainty. You can explore the broader implications of peptide standardisation across our research peptide collection and see how batch-level quality control applies across multiple compound classes.

MK677 same as MK-677 in every way that matters for research validity. The hyphen is a bibliographic quirk, not a pharmacological boundary. Focus on purity, bioavailability, and CoA verification, and the naming variation becomes irrelevant.

References

Peer-reviewed sources on MK-677 (Ibutamoren) indexed in PubMed, listed for research context. Real Peptides supplies MK-677 (Ibutamoren) for laboratory research use only.

Hepatotoxicity induced by MK-677. BMJ case reports, 2025. PMID 40675653. doi:10.1136/bcr-2025-265728
LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental physiology, 2022. PMID 36303408. doi:10.1113/EP090741
Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei medical journal, 2018. PMID 30450851. doi:10.3349/ymj.2018.59.10.1174
Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology, 2008. PMID 19015485. doi:10.1212/01.wnl.0000335163.88054.e7
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism, 1998. PMID 9467534. doi:10.1210/jcem.83.2.4551
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 1997. PMID 9349662. doi:10.1159/000127249
Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences of the United States of America, 1995. PMID 7624358. doi:10.1073/pnas.92.15.7001

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Yes — MK677 and MK-677 are identical. Both designations refer to ibutamoren (C27H36N4O5S, CAS 159752-10-0), a non-peptide growth hormone secretagogue that binds the GHSR-1a receptor. The hyphen is a formatting convention from the original Merck research designation, not a chemical distinction. PubChem lists both forms as synonyms under the same compound identifier (CID 9939050), confirming they reference the same molecule with the same pharmacological properties.

Supplier catalogues often drop the hyphen for informal shorthand or search optimisation — MK677 without punctuation appears in product listings, forum discussions, and non-peer-reviewed summaries more frequently than the hyphenated form. This does not indicate a different compound. The mesylate salt form (ibutamoren mesylate, molecular weight 624.77 g/mol) remains chemically identical whether the label reads MK677, MK-677, or MK 677. Verify identity through certificate of analysis molecular weight and HPLC purity data, not name formatting.

Yes, if the certificate of analysis confirms molecular weight 624.77 g/mol (mesylate salt) or 528.66 g/mol (free base) and purity ≥98%. Dosing recommendations are tied to the compound’s pharmacokinetics — specifically its 24-hour half-life and oral bioavailability of 60–65% — not the presence or absence of a hyphen in the product name. Cross-reference batch numbers and CoA data to ensure the material matches published ibutamoren specifications before applying literature-derived dosing ranges.

MK-677 is a non-peptide spiro-indane derivative with oral bioavailability exceeding 60%, while GHRP-6, GHRP-2, and hexarelin are peptide chains requiring subcutaneous injection due to rapid proteolytic degradation in the gut. MK-677’s small-molecule structure resists enzymatic breakdown, allowing once-daily oral dosing with a 24-hour half-life. Peptide secretagogues have half-lives under 30 minutes and require multiple daily injections to maintain therapeutic plasma levels, making MK-677 pharmacokinetically superior for sustained GH elevation studies.

Research-grade ibutamoren mesylate should demonstrate ≥98% purity by HPLC, confirmed through third-party certificate of analysis showing single-peak chromatograms and mass spectrometry molecular ion detection at m/z 625. Formulations below 95% purity contain synthesis byproducts or degradation compounds that introduce dosing variability and complicate data interpretation. Suppliers listing MK677 at 99%+ purity without CoA documentation should be treated as unverified — request batch-specific HPLC and MS reports before purchase.

No — MK-677 works through the ghrelin pathway (GHSR-1a receptor activation), which stimulates endogenous GH release from the pituitary rather than introducing exogenous GH directly. This mechanism preserves hypothalamic-pituitary feedback loops, so the body continues producing GHRH and responding to regulatory signals. Unlike exogenous GH injection, which suppresses endogenous secretion through negative feedback, MK-677 maintains physiological pulsatile GH patterns while elevating baseline secretion amplitude.

Published clinical trials use 10–25mg daily oral dosing, with 25mg being the most common in sarcopenia and bone density studies. At this dose, serum IGF-1 increases 60–90% from baseline within two weeks, with peak elevations 4–6 hours post-administration. Lower doses (10–15mg) produce proportionally smaller IGF-1 responses but may reduce appetite stimulation — a dose-dependent side effect mediated through ghrelin pathway activation. Research protocols rarely exceed 25mg daily due to diminishing returns on GH secretion above that threshold.

Store unreconstituted lyophilised ibutamoren mesylate at −20°C in sealed vials protected from light and moisture. Under these conditions, the compound maintains ≥98% potency for 24 months. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 30 days — aqueous solutions degrade faster than lyophilised powder due to hydrolytic and oxidative processes. Avoid repeated freeze-thaw cycles, which accelerate degradation and reduce bioavailability in subsequent doses.

MK-677 is frequently paired with compounds like [CJC1295 Ipamorelin](https://www.realpeptides.co/products/cjc1295-ipamorelin-5mg-5mg/) in research protocols investigating synergistic GH pathway activation. Because MK-677 acts on the ghrelin receptor while CJC-1295 amplifies GHRH signaling, their mechanisms are complementary rather than redundant — combined administration can produce greater IGF-1 elevations than either compound alone. Always verify compatibility through published literature and establish separate dosing schedules to isolate individual compound effects during pilot phases.

The most common documented effect is increased appetite, reported by 60–80% of participants in Phase II trials and directly mediated through ghrelin receptor activation. Secondary effects include transient water retention (edema in 10–15% of subjects), mild insulin resistance at doses above 25mg daily, and elevated fasting glucose in pre-diabetic populations. These effects are dose-dependent and typically resolve within 4–8 weeks as metabolic adaptation occurs. Serious adverse events are rare in published trials when dosing remains within 10–25mg daily range.

Reputable research suppliers provide batch-specific certificates of analysis (CoA) that include HPLC chromatograms, mass spectrometry molecular ion detection, and purity percentage calculated from peak integration. Request these documents before purchase — CoAs should reference the specific batch number on your product vial and be dated within 12 months of synthesis. Independent analytical laboratories like Colmaric Analyticals or Janoshik Analytical conduct third-party testing for peptide and research compound suppliers. If a supplier cannot provide recent third-party CoA documentation, consider the material unverified.

Serum IGF-1 elevation becomes measurable within 7–14 days of daily MK-677 administration at 25mg oral dosing, with peak levels typically occurring at week 4–6. The Journal of Clinical Endocrinology & Metabolism published data showing mean IGF-1 increases of 60–90% from baseline by week 2, sustained throughout 12-month administration periods without tachyphylaxis. Individual response timing varies based on baseline GH status, age, and nutritional intake — populations with pre-existing GH deficiency show faster and more pronounced IGF-1 responses.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA